MabVax Therapeutics Secures $5,250,000 New Financing

  • Feed Type
  • Date
    11/23/2012
  • Company Name
    MabVax Therapeutics
  • Mailing Address
    11588 Sorrento Valley Road San Diego, CA 92121
  • Company Description
    MabVax Therapeutics, Inc. is a San Diego, California based immunotherapeutics discovery and development company focused on developing and commercializing novel vaccines and human antibodies for the treatment of cancer. The company was formed to exploit the key aspects of the work of Dr. Philip Livingston and colleagues who over the last 25 years have developed monovalent cancer vaccines against 10 distinct antigenic targets on various types of cancer cells. The Company plans to commercially develop polyvalent versions of the already developed monovalent vaccines against small cell lung cancer (SCLC), sarcoma, melanoma, and other cancers. Concurrently, MabVax will create a pipeline of fully human monoclonal antibody products against each of the target antigens by using both the vaccines and the lymphocytes from successfully vaccinated patients participating in vaccine clinical trials scheduled to begin this year as starting materials for its antibody generation program.
  • Website
    http://www.mabvax.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $5,250,000
  • Transaction Round
    Undisclosed
  • Proceeds Purposes
    The additional capital will allow MabVax to continue the development of its phase 2 vaccine aimed at preventing recurrent sarcoma and its 5B1 antibody program targeting metastatic pancreatic cancer.
  • M&A Terms
  • Venture Investor
    Numoda Capital Innovations
  • Venture Investor
    Burrill & Company
  • Venture Investor
    RTP Ventures

By posting a comment, you agree to our terms and conditions.